Computational approaches to the design of novel 5-HT6R ligands

Reviews in the Neurosciences

Volumn 25, Issue 3, 2014, Pages 451-467

  Ivanenkov, Yan A ^a,b,c   Majouga, Alexander G ^d   Veselov, Mark S ^c   Chufarova, Nina V ^c   Baranovsky, Sergey S ^b   Filkov, Gleb I ^b  

^a CHEMDIV INC   (United States)

^b Chemical Diversity Research Institute   (Russian Federation)

^c MOSCOW INSTITUTE OF PHYSICS AND TECHNOLOGY   (Russian Federation)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Antagonists; Docking; In silico; Pharmacophore; QSAR

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; AMITRIPTYLINE; AVN 211; BENZIMIDAZOLE; BVT 74316; CLOZAPINE; DIMEBON; DOXEPIN; GSK 215083; IDALOPIRDINE; NORTRIPTYLINE; OLANZAPINE; PF 01913539; PF 05212377; PF 5212377; PRX 07034; PRX 07034 001; QUETIAPINE; R 1485; RP 5063; SAM 760; SAX 187; SB 737050A; SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SUVN 502; UNCLASSIFIED DRUG; UNINDEXED DRUG; WAY 181187; WYE 103760; LIGAND; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT;

ACCURACY; ALZHEIMER DISEASE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; COGNITIVE DEFECT; COMPUTER MODEL; DEGENERATIVE DISEASE; DRUG DESIGN; HUMAN; HUNTINGTON CHOREA; MEMORY DISORDER; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PARKINSON DISEASE; PHARMACOPHORE; PSYCHOSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SCHIZOPHRENIA; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMISTRY; COMPUTER AIDED DESIGN; COMPUTER SIMULATION; MENTAL DISEASE; METABOLISM;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; COMPUTER SIMULATION; COMPUTER-AIDED DESIGN; DRUG DESIGN; HUMANS; LIGANDS; MENTAL DISORDERS; RECEPTORS, SEROTONIN; SEROTONIN AGENTS;

EID: 84907170901     PISSN: 03341763     EISSN: 21910200     Source Type: Journal    
DOI: 10.1515/revneuro-2014-0030     Document Type: Review

References (62)

1. Ahmed M. Briggs M.A. Bromidge S.M. Buck T. Campbell L. Deeks N.J. Garner A. Gordon L. Hamprecht D.W. Holland V. et al. (2005). Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists. Bioorg. Med. Chem. Lett. 15 4867-4871
2. Arnt J. and Olsen C.K. (2011). 5-HT6 receptor ligands and their antipsychotic potential. Int. Rev. Neurobiol. 96 141-161
3. Borsini F. Bordi F. and Riccioni T. (2010). 5-HT6 pharmacology inconsistencies. Pharmacol. Biochem. Behav. 98 169-172
4. Bourson A. Borroni E. Austin R.H. Monsma F.J. Jr. and Sle ight A.J. (1995). Determination of the role of the 5-HT6 receptor in the rat brain a study using antisense oligonucleotides. J. Pharmacol. Exp. Ther. 274 173-180
5. Branchek T.A. and Blackburn T.P. (2000). 5-HT6 receptors as emerging targets for drug discovery. Annu. Rev. Pharmacol. Toxicol. 40 319-334
6. Cano-Cuenca N. Solí s-García del Pozo J.E. and Jordán J. (2014). Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J. Alzheimers Dis. 38 155-164
7. Cole C.D. Stock R.J. Lennox J.W. Bernotas C.R. Ellingboe J.W. Boikess S. Coupet J. Smith D.L. Leung L. Zhang G.M. et al. (2007). Discovery of N1-(6-chloroimidazo(21-b) (13)-thiazole-5-sulfonyl)tryptamine as a potent selective and orally active 5-HT6 receptor agonist. J. Med. Chem. 50 5535-5538
8. De la Fuente T. Martí n-Fontecha M. Sallander J. Benhamú B. Campillo M. Medina R.A. Pellissier L.P. Claeysen S. Dumuis A. Pardo L. et al. (2010). Benzimidazole deriva tives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation. J. Med. Chem. 53 1357-1369
9. Devegowda V.N. Hong J.R. Cho S. Lim E.J. Choo H. Keum G. Rhim H. and Nam G. (2013). Synthesis and the 5-HT6 receptor antagonistic effect of 3-arylsulfonylamino-56-dihydro-6-substituted pyrazolo[34]pyridinones for neuropathic pain treatment. Bioorg. Med. Chem. Lett. 23 4696-4700. Epub 2013 Jun 18
10. Doddareddy M.R. Lee Y.J. Cho Y.S. Choi K.I. Koh H.Y. and Pae A.N. (2004a ). Hologram quantitative structure activity relationship studies on 5-HT6 antagonists. Bioorg. Med. Chem. 12 3815-3824
11. Doddareddy M.R. Cho Y.S. Koh H.Y. and Pae A.N. (2004b ). CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists. Bioorg. Med. Chem. 12 3977-3985
12. Dukat M. Mosier P.D. Kolanos R. Roth B.L. and Glennon R.A. (2008). Binding of serotonin and N1-benzenesulf onyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J. Med. Chem. 51 603-611
13. Gavrilova S. Sano M. Thomas R. Aisen P. Bachurin S. Seely L. and Hung D. (2007). Results of a one-year randomized placebo-controlled trial of Dimebon for the treatment of mild to moderate Alzheimer's disease. Alzheimer's Assoc. Int. Conf. Prev. Dement. Abstr. S3-02-03
14. Gerard C. Mestika wy S. Lebrand C. Adrien J. Ruat M. Traiffort E. Hamon M. and Martres M.P. (1996). Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 57-dihydroxytrypt amine-treated rats. Synapse 23 164-173
15. Glennon R.A. Siripurapu U. Roth B.L. Kolanos R. Bondarev L. Sikazwe D. Lee M. and Dukat M. (2010). The medicinal chemistry of 5-HT6 re ceptor ligands with a focus on arylsulfonyltryptamine analogs. Curr. Top. Med. Chem. 10 579-595
16. Goodarzi M. Freitas M.P. and Ghasemi N. (2010). QSAR studies of bioactivities of 1-(azacyclyl)-3-ar ylsulfonyl-1H-pyrrolo[23-b] pyridines as 5-HT6 receptor ligands using physicochemical descriptors and MLR and ANN-modeling. Eur. J. Med. Chem. 45 3911-3915. Epub 2010 May 31
17. Hamon M. Doucet E. Lefevre K. Miquel M.-C. Lanfumey L. Insausti R. Frechilla D. Del Rio J. and Verge D. (1999). Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. Neurop sychopharmacology 21 68S-76S
18. Hao M. Li Y. Li H. and Zhang S. (2011). Investigation of the structure requirement for 5-HT(6) binding affinity of arylsulfonyl derivatives: a computational study. Int. J. Mol. Sci. 12 5011-5030
19. Hayat F. Cho S. Rhim H. Ambily Nath I.V. Pae A.N. Lee J.Y. Choo D.J. and Choo H.P. (2013). Design and synthesis of novel series of 5-HT6 receptor ligands having indole a central aromatic core and 1-amino-4methyl piperazine as a positive ionizable group. Bioorg. Med. Chem. 21 5573-5582.
20. Hendrix S.,Selby B.,Seely L.,Cummings J, 2009, Disease modifying effect of Dim ebon in Alzheimer's disease: results from a 12-month study of Dimebon and a 6-month open-label period analyzed using a staggered start approach and a natural-history staggered start (NHSS) approach. 61st Annu. Meet. Am. Acad. Neurol. Abstr, P06.074.
21. Holenz J. Mercè R. Díaz J.L. Guitart X. Codony X. Dordal A. Romero G. Torrens A. Mas J. Andaluz B. et al. (2005). Medicinal chemistry driven approaches towards novel and se lective serotonin 5-HT6 receptor ligands. J. Med. Chem. 48 1781-1795
22. Holenz J. Pauwels P.J. D íaz J.L. Mercè R. Codony X. and Buschmann H. (2006). Medicinal chemistry strategies to 5-HT(6 ) receptor ligands as potential cognitive enhancers and antiobesity agents. Drug Discov. Today 11 283-299
23. Hostetler G. Dunn D. McKenna B.A. Kopec K. and Chatterjee S. (2014). In search of potent 5-HT6 receptor inverse agonists. Chem. Biol. Drug. Des. doi: 10.1111/cbdd.12279.0. Epub 2014 January 9
24. Ivachtchenko A.V. Golovina E.S. Kadieva M.G. Koryakova A.G. Kovalenko S.M. Mitkin O.D. Okun I.M. Ravnyeyko I.M. Tkachenko S.E. and Zaremba O.V. (2010). Synthesis and biological study of 3-(phenylsulfonyl)thieno[23-e][123] triazolo[15-a]pyrimidines as potent and selective serotonin 5-HT6 receptor antagonists. Bioorg. M ed. Chem. 18 5282-5290
25. Ivanenkov Y.A. and Khandarova L.M. (2010). Advanced artificial intelligence methods used in the design of pharmaceutical agents. In: Pharmaceutical Data Mining: Approaches and Application s for Drug Discovery. S. Ekins ed. (Wiley Hoboken New Jersey USA: Wiley & Sons Inc.) pp. 457-490
26. Kieburtz K. (2009). The safety and efficacy of Dimebon in mildto-moderate Huntington's disease: a multicenter phase 2 randomized placebo-controlled trial (DIMOND). 9th Int. Conf. Alzheimer Parkinson Dis. (abstract
27. Kieburtz K. McDermott M.P. Voss T.S. Corey-Bloom J. Deuel L.M. Dorsey E.R. Factor S. Geschwind M.D. Hodgeman K. Kayson E. et al. (2010). A randomized placebo-controlled trial of latrepirdine in Huntington disease. Arch. Neurol. 67 154
28. Kim H.J. Doddareddy M.R. Choo H. Cho Y.S. No K.T. Park W.K. and Pae A.N. (2008). New serotonin 5-HT(6) ligands from common feature pharmacophore hypotheses. J. Chem. Inf. Model 48 197-206
29. King M.V. Sleight A.J. Woolley M.L. Topham I.A. Marsden C.A. and Fone K.C. (2004). 5HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation-an effect sensitive to NMDA receptor antagonism. Neuro pharmacology 47 195-204.
30. Kiselyov A.S. (2006). Biology-driven diversity: concept of focused diversity. Chem. Biol. Drug. Des. 68 67-69
31. Kohen R. Metcalf M.A. Khan N. Druck T. Huebner K. Lachowicz J.E. Meltzer H.Y. Sibley D.R. Roth B.L. and Hamblin M.W. (1996). Cloning characterization and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66 47-56
32. Kombo D.C. Tallapragada K. Jain R. Chewning J. Mazurov A.A. Speake J.D. Hauser T.A. and Toler S. (2013). 3D molecular descriptors important for clinical success. J. Chem. Inf. Model 53 327-342
33. Kortagere S. Chekmarev D. Welsh W.J. and Ekins S. (2008). New predictive models for blood-brain barrier permeability of druglike molecules. Pharm. Res. 25 1836-1845
34. Landwehrmeyer B.G. Kieburtz K. and Noonberg S. (2010). A phase-3 safe ty and efficacy study of Dimebon in patients with mild-to-moderate Huntington's disease-an ongoing clinical trial. Eur. J. Neurol. 17 abstract P1020
35. Lesem M. (2007). A randomized placebo-controlled phase IIa trial of SGS518 for treating cognitive impairment associated with schizophrenia. 11th Int. Congr. Schizophr. Res. (abstract).
36. Liu K.G. Lo J.R. Comery T.A. Zhang G.M. Zhang J.Y. Kowal D.M. Smith D.L. Di L. Kerns E.H. Schechter L.E. et al. (2009a ). Identification of a series of benzoxazoles as potent 5-HT6 ligands. Bioorg. Med. Chem. Lett. 19 1115-1117
37. Liu K.G. Lo J.R. Comery T.A. Zhang G.M. Zhang J.Y. Kowal D.M. Smith D.L. Di L. Kerns E.H. Schechter L.E. et al. (2009 b ). 1-Sulfonylindazoles as potent and selective 5-HT6 ligands. Bioorg. Med. Chem. Lett. 19 2413-2415
38. Liu K.G. Robichaud A.J. Bernotas R.C. Yan Y. Lo J.R. Zhang M.Y. Hughes Z.A. Huselton C. Zhang G.M. Zhang J.Y. et al. (2010). 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-HT6 antagonists. J. Med. Chem. 53 7639-7646.
39. López-Rodrí guez M.L. Benhamú B. de la Fuente T. Sanz A. Pardo L. and Campillo M. (2005). A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J. Med. Chem. 48 4216-4219
40. Lundbeck Report (2010). First Quarter Report 2010-Lundbeck Delivers Strong Growth-and Is Off to a Very Good Start to Achieve Full Year Guidance. Available online at: http://investor. lundbeck.com/releasedeta il.cfm?ReleaseID = 608594
41. Lundbeck Study Record (2014). Study of Lu AE58054 in Patients with Mild-Moderate Alzheimer's Disease Treated with Donepezil (STARSHINE). Available online at: http://clinicaltrials.gov/ct2/show/NCT0195516 1
42. Maher-Edwards G. Dixon R. Hunter J. Gold M. Hopton G. Jacobs G. Hunter J. and Williams P. (2011). SB-742457 and donepezil in Alzheimer disease: a randomized placebo-controlled study. Int. J. Geriatr. Psychiatry 26 536-544.
43. Monsma Jr. F.J.,Shen Y.,Ward R.P.,Hamblin M.W.,Sibley D.R., 1993, Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs, Mol. Pharmacol, 43, 320-327.
44. Murphy D.L. Andrews A.M. Wichems C.H. Li Q. Tohda M. and Greenberg B. (1998). Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity multiple receptors interactions with other neurotransmitter systems and consequent implications for understanding the actions of serotonergic drugs. J. Clin. Psychiatry 59 4-12
45. Pfizer Study Record (2012). Study Comparing 3 Dosage Levels of SAM-531 in Outpatients with Mild to Moderate Alzheimer Disease. Available online at: http://clinicaltrials.gov/ct2/show/results/NCT00895895ńsect = X3015#evnt
46. Pullagurla M.R. Westkaemper R.B. and Glennon R.A. (2004). Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg. Med. Chem. Lett. 14 4569-4573
47. Rajagopala n R. Bandyopadhyaya A. Rajagopalan D.R. and Rajagopalan P. (2014). The synthesis and comparative receptor binding affinities of novel isomeric pyridoindolobenzazepine scaffolds. Bioorg. Med. Chem. Lett. 24 576-579.
48. Rapport M.M. Green A.A. and Page I.H. (1948 a ). Serum vasoconstrictor serotonin; chemical inactivation. J. Biol. Chem. 176 1237-1241
49. Rapport M.M. Green A.A. and Page I.H. (1948 b ). Serum vasoconstrictor serotonin; isolation and characterization. J. Biol. Chem. 176 1243-1251
50. Rogers D.C. and Hagan J.J. (2001). 5-HT6 receptor antagonists enhance retention of a water maze task in the rat. Psychopharmacology 158 114-119
51. Romero G. Pujol M. Pé rez P. Buschmann H. and Pauwels P.J. (2007). Whole spectrum analysis of ligand efficacy at constitutively active human wild-typ e and S267K 5-HT6 receptors in HEK-293F cells. J. Pharmacol. Toxicol. Methods 55 144-150
52. Roth B.L. Craigo S.C. Choudhary M.S. Uluer A. Monsma F.J. Jr. Shen Y. Meltzer H.Y. and Sibley D.R. (1994). Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268 1403-1410
53. Ruat M. Traiffort E. Arrang J.M. Tardivel-Lacombe J. Diaz J. Leurs R. and Schwartz J.C. (1993). A novel rat serotonin (5-HT6) receptor: molecular cloning localization and stimulation of cAMP accumulation. Biochem. Biophys. Res. Commun. 193 268-276
54. Schechter L.E. Lin Q. Smith D.L. Zhang G. Shan Q. Platt B. Brandt M.R. Dawson L.A. Cole D. Bernotas R. et al. (2008). Neuropharmacological profile of novel and selectiv e 5-HT(6) receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 33 1323-1335
55. Sharma B.K. Singh P. Sarbhai K. and Prabhakar Y.S. (2010). A quantitative structure-activity relationship study on serotonin 5-HT(6) receptor ligands: indolyl and piperidinyl sulphonamides. SAR QSAR Environ. Res. 21 369-388
56. Sleight A.J. Monsma F.J. Jr. Borroni E. Austin R.H. and Bourson A. (1996). Effects of altered 5-HT6 expression in the rat: functional studies using antisense oligonucleotides. Behav. Brain Res. 73 245-248
57. Sleight A.J. Boess F.G. Bos M. Levet-Trafit B. Riemer C. and Bourson A. (1998). Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br. J. Pharmacol. 124 5 56-562
58. Suenderhauf C. Hammann F. and Huwyler J. (2012). Computational prediction of blood-brain barrier permeability using decision tree induction. Molecules 17 10429-10445
59. Tasler S. Kraus J. Wuzik A. Müller O. Aschenbrenner A. Cubero E. Pascual R. Quintana-Ruiz J.R. Dordal A. Mercè R. et al. (2007). Discovery of 5-HT6 receptor ligands based on virtual HTS. Bioorg. Med. Chem. Lett. 17 6224-6229
60. Ward R.P. Hamblin M.W. Lachowicz J.E. Hoffman B.J. Sibley D.R. and Dorsa D.M. (1995). Localization of serotonin subtype 6 receptor messenge r RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 64 1105-1111
61. Woods S. Clarke N.N. Layfield R. and Fone K.C. (2012). 5-HT(6) receptor agonists and antagonists enhance le arning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br. J. Pharmacol. 167 436-449
62. Woolley M.L. Marsden C.A. and Fone K.C. (2004). 5-HT6 receptors. Curr. Drug Targets CNS Neurol. Disord. 3 59-79.